Home > Press > Lumera Corporation Announces Shelf Registration
Lumera Corporation (NASDAQ:LMRA), a leader in the emerging field of nanotechnology, today announced that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC).
Lumera Corporation Announces Shelf Registration
BOTHELL, WA | Posted on July 18th, 2007
Upon being declared effective by the SEC, the registration statement will allow Lumera to offer and sell, from time to time, in one or more offerings, shares of its common stock, shares of its preferred stock, debt securities, warrants, or any combination of such securities, for proceeds in the aggregate amount up to $50 million. The terms of any such future offering will be established at the time of the offering. Proceeds from the sale of any securities will be used for the purposes described in the prospectus or a prospectus supplement filed at the time of an offering. Lumera has no immediate plans to offer or sell any securities under the registration statement.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. A copy of the registration statement may be obtained at www.sec.gov. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Lumera Corporation
Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices.
Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.
For more information, please click here
Helene F. Jaillet, Ph.D.
The Summit Group Communications
Copyright © Lumera Corporation
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Pixelligent Closes $5.5 Million in Funding: Capital Will Be Used to Support Global Customer Growth December 12th, 2014
Nanometrics Announces Upcoming Investor Events November 19th, 2014
Eight19 secures £1m funding: Investment to develop production technology, and expand commercial activities for organic photovoltaics November 19th, 2014
Arrowhead to Present at Upcoming Conferences November 15th, 2014
New non-invasive method can detect Alzheimer's disease early: MRI probe technology shows brain toxins in living animals for first time December 22nd, 2014
Piezoelectricity in a 2-D semiconductor: Berkeley Lab researchers discovery of piezoelectricty in molybdenum disulfide holds promise for future MEMS December 22nd, 2014
Quantum physics just got less complicated December 22nd, 2014
Enzyme Biosensor Used for Rapid Measurement of Drug December 22nd, 2014